TeraRecon Neuro

TeraRecon Neuro is an advanced image processing software that analyzes dynamic CT and MRI brain perfusion datasets to generate quantitative parametric maps and visualizations, including Tmax, mismatch, and hypoperfusion maps. Its purpose is to provide clinicians with tools for enhanced diagnosis, clinical decision support, treatment planning, and post-treatment evaluation in neurological conditions by offering detailed insights into brain tissue perfusion and vascular status.

TeraRecon Neuro version 2.0.0 is an image processing software device designed for the analysis of dynamic brain perfusion image data acquired via CT or MRI. It performs motion correction and calculates various parameters related to brain tissue perfusion, vascular assessment, and tissue blood volume. The software outputs include parametric maps such as time to peak (TTP), mean transit time (MTT), blood volume (BV), blood flow (BF), and newly added maps for CT modality: time to maximum (Tmax), hypoperfusion maps, and mismatch (penumbra/umbra) maps with associated volumes and ratios. It also provides 2D and 3D visualizations of brain tissues and blood vessels, including a 'tumble view' for qualitative review of vascular structures in correlation to perfusion maps. The TeraRecon Neuro algorithm is intended for use by trained healthcare professionals, including physicians and surgeons, to aid in diagnosis, clinical decision support, treatment planning, and post-treatment evaluation. It can be deployed as a Microsoft Windows executable or a containerized application on off-the-shelf hardware or cloud platforms. The results can be viewed through systems like TeraRecon's Intuition or Eureka, or other DICOM-compliant viewers. The software is an update to the predicate Neuro.AI Algorithm (K200750), with key enhancements being the addition of Tmax, hypoperfusion, and mismatch maps, alongside improvements to existing perfusion map quality. Performance was validated through software testing, quantitative phantom testing, and qualitative clinical user evaluation against predicate and reference devices.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the motion correction algorithm in TeraRecon Neuro version 2.0.0 compare in accuracy and processing time to other standard motion correction techniques for dynamic brain imaging?; What are the specific algorithms or mathematical models underpinning the calculation of the newly added perfusion maps (Tmax, Hypoperfusion, Mismatch), and how were they validated beyond qualitative comparison with reference devices?; What is the typical processing time for a standard CT or MRI brain perfusion dataset using TeraRecon Neuro, and how does this scale with dataset size or complexity?; Are there any known limitations or contraindications for using TeraRecon Neuro with specific patient populations (e.g., pediatric, patients with severe motion artifacts) or in the presence of particular imaging artifacts not fully corrected by the software?; Beyond the qualitative assessment and Tmax quantitative evaluation against reference devices, what further studies are planned to assess the impact of TeraRecon Neuro on diagnostic accuracy, inter-rater reliability, or clinical outcomes for specific neurological conditions like acute ischemic stroke?